echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > JAMA: Kidney transplant recipients should receive three doses of mRNA-1273 SARS-CoV-2 vaccine

    JAMA: Kidney transplant recipients should receive three doses of mRNA-1273 SARS-CoV-2 vaccine

    • Last Update: 2021-07-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The study reported that solid organ transplant recipients who received the new mRNA coronavirus vaccine had a lower seroconversion rate (58% after the second dose).
    Based on this evidence, the French National Health Agency issued a report in April 2021.
    It is recommended that immunosuppressed patients who do not respond after two doses receive a third dose of vaccine
    .

    The study reported that solid organ transplant recipients who received the new mRNA coronavirus vaccine had a lower seroconversion rate (58% after the second dose).
    Based on this evidence, the French National Health Agency issued a report in April 2021.
    It is recommended that immunosuppressed patients who do not respond after two doses receive a third dose of vaccine
    .


    immunity

    Ilies Benotmane et al.
    examined the antibody response of kidney transplant recipients who did not respond to two doses and received a third dose (100 μg) of mRNA-1273 vaccine (Moderna)
    .


    The results of the study were published in JAMA magazine


    Ilies Benotmane et al.


    All kidney transplant recipients will be followed up in the Kidney Transplant Department of the University Hospital of Strasbourg from January 20, 2021 to June 3, 2021, on the day of the first vaccination and after the second vaccination In 1 month, COVID-19 and SARS-CoV-2 anti-plague IgG levels were lower than 50 arbitrary units (AU)/mL on average
    .


    All patients received the third dose of vaccine between April 9, 2021 and May 12, 2021


    All kidney transplant recipients will be followed up in the Kidney Transplant Department of the University Hospital of Strasbourg from January 20, 2021 to June 3, 2021, on the day of the first vaccination and after the second vaccination In 1 month, COVID-19 and SARS-CoV-2 anti-plague IgG levels were lower than 50 arbitrary units (AU)/mL on average


    One month after the second dose of vaccine, the IgG levels of 159 kidney transplant recipients were below 50 Au/ml


    Compared with non-antibody responders, patients with a weak response after the second dose are more likely to develop an antibody response after the third dose (81.
    3% and 27.
    4%, respectively; the average corrected antibody titer difference is 894.
    89Au/ml [95 %CI, 377.
    41-1410.
    37]; P=0.
    001)
    .


    Patients taking tacrolimus, mycophenolate and steroids are less likely to develop anti-SARS-CoV-2 antibodies than patients treated with other regimens (35% and 63%, respectively; average adjusted antibody titers are poor, -697.


    Compared with non-antibody responders, patients with a weak response after the second dose are more likely to develop an antibody response after the third dose (81.


    This study found that the third dose of mRNA-1273 vaccine induced a serological response in 49% of kidney transplant recipients who did not respond after two doses
    .


    The findings of this large group of kidney transplant recipients are consistent with studies of other solid organ transplant recipients


    This study found that the third dose of mRNA-1273 vaccine induced a serological response in 49% of kidney transplant recipients who did not respond after two doses


    Original source

    Benotmane I, Gautier G, Perrin P, et al.


    Benotmane I, Gautier G, Perrin P, et al.
    Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses.
    JAMA.
    Published online July 23, 2021.
    doi:10.
    1001/jama.
    2021.
    12339 Benotmane I, Gautier G, Perrin P, et al.
    Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses.
      JAMA.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.